- Home
- NTIP vs TPST Comparison
NTIP vs TPST Comparison
Compare NTIP & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | TPST |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 30.9M |
| IPO Year | 2013 | 2012 |
Fundamental Metrics
Financial Performance| Metric | NTIP | TPST |
|---|---|---|
| Price | $1.40 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 491.2K | 273.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $1.16 | $1.50 |
| 52 Week High | $1.75 | $12.22 |
Technical Indicators
Market Signals| Indicator | NTIP | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 41.20 |
| Support Level | $1.34 | $1.50 |
| Resistance Level | $1.47 | $2.48 |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 27.08 | 16.48 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.